Pierce David A 4

4 · BOSTON SCIENTIFIC CORP · Filed Feb 22, 2022

Form 4

Period: 2022-02-17

SVP and President, Endoscopy

Transactions

Exercise/Conversion
Deferred Stock Units
2022-02-18−2,668→ 5,337 total
Exp: 2024-02-18→ Common Stock (2,668 underlying)
Exercise/Conversion
Common Stock
2022-02-17+3,333→ 3,333 total
Tax Payment
Common Stock
2022-02-17$42.83/sh−979$41,931→ 2,354 total
Exercise/Conversion
Common Stock
2022-02-18+2,668→ 5,022 total
Sale
Common Stock
2022-02-18$42.88/sh−2,354$100,940→ 1,884 total
Tax Payment
Common Stock
2022-02-18$42.55/sh−784$33,359→ 4,238 total
Exercise/Conversion
Restricted Stock Units
2022-02-17−3,333→ 10,000 total
Exp: 2025-02-17→ Common Stock (3,333 underlying)

Footnotes (5)

[F1]Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
[F2]Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
[F3]The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-l trading plan.
[F4]Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant.
[F5]Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant.

Documents

1 file